NEBIVOLOL A NOVEL SOMEWHAT DIFFERENT Î’ETA ADRENERGIC RECEPTOR BLOCKER
Nebivolol is a highly selectiveÂ Î²1 adrenoceptor blocker available clinically and is devoid of intrinsic sympathomimetic activity, inverse agonistic activity, and Î±1 receptor blocking properties along with peripheral vasodilatation and nitric oxide (NO) induced benefits such as antioxidant activity and reversal of endothelial dysfunction. Nebivolol is the racemic mixture of 2 isomers with 4 asymmetric centres. The d-isomer is the active b-blocking component, while the l-isomer is responsible for the release of nitric oxide. Nebivolol has a hemodynamic profile different from classic Î² receptor antagonists that iit acutely lowers arterial blood pressure without depressing left ventricular function, and reduces systemic vascular resistance. Nebivolol shown to inhibitÂ platelet aggregation and thrombus formation, itÂ hasÂ also an antiproliferative effects and reverses endothelial dysfunction in animal models of oxidative stress.Â Clinically, this compound has been proven to have antihypertensive and anti-ischemic effects as well as beneficial effects on hemodynamics. The tolerability of nebivolol has been shown to be superior to that of other beta blocker. Further studies are now necessary to compare the benefit of nebivolol with that of other drugs in the same class and to prove its claims of superiority and novelty of action, most importantly, its prognostic impact in patients with hypertension and its potential benefit in other comorbid conditions.Keywords- Nebivolol, Î²1 adrenoceptor blocker.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).